All In Biotech

Drug Trial Radar · NCT06884085

A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-227 Compared to Co-administration of AD-227A and AD-227B in Healthy Adult Volunteers Under Fasting Conditions

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Jul 12, 2025

Primary completion

Aug 13, 2025

Study completion Aug 13, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Mar 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.

Conditions

  • Primary Hypertension

Interventions

  • Co-administration of AD-227A and AD-227BDrug

    Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral

  • Administration of AD-227Drug

    Administration of AD-227 1Tab., Per Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose (0hour) to 72hours
  2. Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose (0hour) to 72hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Central Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.